Multimodal therapy of malignant pleural mesothelioma: Is the replacement of radical surgery imminent?

Interactive Cardiovascular and Thoracic Surgery

Volumn 16, Issue 3, 2013, Pages 237-243

  Lindenmann, Joerg ^a   Matzi, Veronika ^a   Neuboeck, Nicole ^a   Anegg, Udo ^a   Maier, Alfred ^a   Smolle, Josef ^a   Smolle Juettner, Freyja Maria ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Mesothelioma; Palliative care; Pleural disease; Thoracic surgery

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; FOLIC ACID; PEMETREXED; PHOTOFRIN; PHOTOFRIN 75; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CHYLOTHORAX; CLINICAL EFFECTIVENESS; DIODE LASER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; LUNG RESECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDIASTINUM LYMPH NODE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PLEURA EFFUSION; PLEURA EMPYEMA; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; PNEUMONIA; PNEUMOTHORAX; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COMORBIDITY; FEMALE; HEALTH STATUS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PATIENT SELECTION; PHOTOCHEMOTHERAPY; PLEURAL NEOPLASMS; PROPENSITY SCORE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; THORACIC SURGICAL PROCEDURES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874287492     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivs465     Document Type: Article

References (25)

1. Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol 2011;12:163-72.
2. Greillier L, Marco S, Barlesi F. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies. Anticancer Drugs 2011;22: 199-205.
3. Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J et al. International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 2011; 6:1304-12.
4. Lindenmann J, Matzi V, Neubock N, Maier A, Smolle-Juttner FM. The clinical impact of photodynamic therapy in thoracic surgery. Eur Surg 2010;42:220-8.
5. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-65.
6. Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallières E. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 2009;88: 870-5.
7. Takagi K. Pleuropneumonectomy: an effective treatment modality for malignant pleural mesothelioma? Ann Thorac Cardiovasc Surg 2008;14: 135-7.
8. Sugarbaker DJ, Jaklitsch MT, Bueno R, Richards W, Lukanich J, Mentzer SJ et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138-46.
9. Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B et al.; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-9.
10. Yan TD, Boyer M, Tin MM, Sim J, Kennedy C, McLean J et al. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Ann Thorac Surg 2009;87:1552-6.
11. Flores RM. Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg 2009;21:149-53.
12. Martin-Ucar AE, Nakas A, Edwards JG, Waller DA. Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007;31:765-70.
13. Sugarbaker DJ, Wolf AS, Chirieac LR, Godleski JJ, Tilleman TR, Jaklitsch MT et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg 2011;40:298-303.
14. Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact CardioVasc Thorac Surg 2008;7:102-6.
15. Stewart DJ, Martin-Ucar A, Pilling JE, Edwards JG, O'Byrne KJ, Waller DA. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg 2004; 78:245-52.
16. Bölükbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011;71:75-81.
17. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J et al.; MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72.
18. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-6, 626.e1-3.
19. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008;34: 886-91.
20. Zahid I, Sharif S, Routledge T, Scarci M. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma? Interact CardioVasc Thorac Surg 2011; 12:812-7.
21. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006;1: 591-601.
22. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
23. Ris HB. Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma. Lung Cancer 2005;49(Suppl 1):S65-8.
24. Friedberg JS. Photodynamic therapy for malignant pleural mesothelioma: the future of treatment? Expert Rev Respir Med 2011;5:49-63.
25. Price A. What is the role of radiotherapy in malignant pleural mesothelioma? Oncologist 2011;16:359-65.